Loading the security page…
A security analysis is not yet prepared for this market.
Based on the last 12 months of reports, through 30 June 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
Share count is a period average, so market cap is approximate.
Aligos Therapeutics, Inc. (ALGS) is a company in the Health care sector; its shares trade on Nasdaq.
The price of Aligos Therapeutics, Inc. (ALGS) on November 12, 2026 is 2.01 $, −6.94 % on the day. Over 52 weeks the stock traded between 1.92 $ and 13.69 $; the price now sits 1 % of the way up that range. Over the past year the price changed by −69.33 %. Market capitalization is 22.32 million $, rank 112 among 134 stocks of the same industry with a known capitalization.
Aligos Therapeutics, Inc. trades on Nasdaq under the ticker ALGS. The company belongs to the Health care sector. The trading history on this page starts on 16 October 2020.
Over the past 52 weeks ALGS has traded between 1.92 $ and 13.69 $. As of 12 November 2026 the price stood 0.51% of the way from the 52-week low to the high.
Over one year ALGS shares fell 69.33%; over six months they fell 70.40%. Volatility over 90 days is 120.64%. Dividends are not included: this is price change only, as of 12 November 2026.
The company reported a loss over the last four quarters, so a price-to-earnings ratio is not calculated. Price to sales is 6.0, above the sector median of 3.9. Price to book is 0.7, below the sector median of 2.4. Calculated from reports for the period ending 30 June 2026.
Aligos Therapeutics, Inc. reported revenue of 4M $ and a net loss of 76M $ over the last four quarters. Net margin is −2,031.07%. Revenue changed by +19.41% year over year. Earnings per share are −$7.71. Market capitalisation is 22M $.
ALGS has a return on equity of −238.24%, below the sector median of −40.58%. Return on assets is −114.53%, below the sector median of −30.08%. Operating margin is −2,112.14%, below the sector median of −20.96%.